Watson biological difficult self-help 700 million yuan to sell hot subsidiary-t6670

Watson biological difficult seek self-help 700 million yuan to sell "hot" subsidiary hot column capital flows thousands of thousands of stocks the latest Rating Rating diagnosis simulated trading client sina finance App: Live on-line blogger to guide your entries you make you take will always let you each reporter Yan Falls Silver Chan "Shandong illegal vaccine series of cases has been in the past few months, Watson is still living in the center of the storm of torment. The morning of September 21st, Watson biological bursts of announcement, said intends to clear transfer subsidiary real Jie 45% stake to Derun biological day in cash transactions, transfer to Yuxi woyun real Jie biological 40% equity, the transaction price is determined as 697 million yuan. After the completion of the transaction, the real biological will also be named from Watson biological subsidiary column. "Daily economic news" reporter noted that Watson’s first half of 2016 net profit also fell sharply, loss of more than 160 million yuan; at the same time, affected by the new deal vaccine, its years to build vaccine circulation platform suffered heavy losses, almost stagnant. "For this company, how to use the plate of the listed company, not waste, is the most critical."." One analyst said, this is the logic behind the operation of Watson biology. The sale of the subsidiary, consistent with the previous market expectations, the suspension for more than 4 months Watson biological or will real biological this "hot potato" sold. Real biological in March this year involved in the "Shandong illegal operation vaccine case", has been revoked "drug business license" and the termination of the National SME stock transfer system listing. The "daily economic news" reporter noted that real Jie biological equity took over the party Derun day clear, Yuxi woyun were actually "own people". Derun, the executive partner of Tian Qing, is the chairman and general manager of Wang Wenhua, and the other limited partners also hold an important position in the company. According to the data of the national enterprise credit information publicity system, Yuxi woyun natural person shareholder of Li Yunchun, investment 316 million yuan, the total contribution rate of 99%. Li Yunchun is also a major shareholder and legal representative of Watson biology. Watson biological also said that the transaction constitutes a connected transaction. The real purpose is to protect the interests of the shareholders, but after all, the profitability of real creatures is worrying." A pharmaceutical listed company executives said to reporters. In fact, Watson has made a lot of efforts to build a vaccine circulation platform in recent years. Reporters learned that the total cost of 1 billion 117 million yuan acquisition of Ningbo real Jie Puno, biology, medicine, union and Chongqing Shengtai Gabriel times Ning shares; then the Chongqing times, and all of the assets of Ningbo Shengtai pharmaceutical Punuo Ning Injection real Jie biological, to build the country’s largest vaccines and other biological products sales channels platform. It is worth noting that the resale price of biological shares has shrunk substantially compared with the previous investment. This price is not up to the investment price

沃森生物艰难谋自救 7亿元出售“烫手”子公司 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经App:直播上线 博主一对一指导 你参赛你赚你拿 总能让你过把瘾   ◎每经记者 鄢银婵   “山东非法经营疫苗系列案件”已过去数月,身处风暴中心的沃森生物仍是备受煎熬。   9月21日早间,沃森生物连发多条公告,表示拟以现金交易的方式向德润天清转让子公司实杰生物45%股权,向玉溪沃云转让实杰生物40%股权,交易总价确定为6.97亿元。本次交易完成后,实杰生物也将从沃森生物子公司一栏中划名。   《每日经济新闻》记者注意到,沃森生物2016年上半年净利润也出现了大幅度下滑,亏损超过1.6亿元;同时,受疫苗新政影响,其多年打造的疫苗流通平台遭受重创,几近停滞。   “对这家公司来说,怎么把上市公司这个盘子利用好,不至于浪费掉,是最关键的。”一位分析人士表示,这也是沃森生物此次运作的背后逻辑。   低价出售子公司   同市场此前预期一致,停牌长达4个多月的沃森生物还是将实杰生物这一“烫手山芋”卖掉了。实杰生物在今年3月卷入“山东非法经营疫苗案”,先后被吊销《药品经营许可证》以及终止在全国中小企业股份转让系统挂牌。   《每日经济新闻》记者注意到,实杰生物的股权接手方德润天清、玉溪沃云实际上均为“自家人”。德润天清的执行事务合伙人为王文华,同时也是实杰生物的董事长兼总经理,其他多名有限合伙人也在实杰生物关联公司担任要职。   而据全国企业信用信息公示系统数据,玉溪沃云的自然人股东为李云春,出资额3.16亿元,占总出资额比例达99%。李云春同时为沃森生物的大股东及法定代表人。沃森生物也表示,此次交易构成关联交易。   “把实杰生物从上市公司盘子里剥离出去,虽然是左手倒右手,但主要目的还是为了维护股东利益,毕竟现在实杰生物的盈利能力堪忧。”一位医药上市公司高管对记者表示。   事实上,沃森生物近年来在打造疫苗流通大平台上下了不少工夫。记者了解到,其先后总计花费11.17亿元收购了宁波普诺、实杰生物、圣泰药业、瑞尔盟以及重庆倍宁的股权;随后又将重庆倍宁、宁波普诺和圣泰药业的全部资产注入实杰生物,欲打造全国最大的疫苗及其他生物制品代理销售渠道平台。   值得注意的是,此次转卖实杰生物股权的价格相比此前的投入,已经大幅缩水。   “这个价格虽然没有达到投资价,但毕竟实杰生物在疫苗领域的渠道优势还是具备的,上市公司之所以没有将它真正出清,未来可能也有将它再吸收合并的想法。”上述高管表示。   未来公司实控人或易主   此外,沃森生物同时发布的另一条公告显示,未来公司实控人还可能会易主。   公告显示,公司与云南省工业投资控股集团有限责任公司(以下简称云南工投)及大股东李云春近期签订《合作协议》,云南工投将通过依法受让李云春及公司其他股东所持股份、参与公司增发、二级市场增持或与李云春及公司管理团队共同搭建控股平台等方式成为公司控股股东。同时,股份转让价格原则上不低于《股份转让协议》签订之日前一交易日大宗交易价格下限。   记者了解到,云南工投为云南省重要的国有资本投资管理平台之一,业务涵盖生物医药、电子信息、园区产业、现代服务业等。而据中诚信国际针对该公司发布的评级报告显示,2013年、2014年该公司合并总营收分别为75.70亿元、67.44亿元,其中医药板块的营收占比在30%以上,下属公司主要为云南医药工业股份有限公司。   “生物医药产业是云南省重点发展的产业,沃森生物这个医药上市公司平台自然就比较珍贵。”上述高管表示,云南工投对沃森生物控股后,也有可能利用该盘子整合自己的医药资源。不过目前可查的公开信息中,尚未出现云南工投及旗下资产有意登录资本市场的消息。   北京鼎臣医药管理咨询负责人史立臣认为,沃森生物之所以引进云南工投,也是为了充实自身实力。“公司自身产品多年来结构单一,种类太少,导致业绩持续亏损,剥离世杰生物后,公司需要注入优质资产充实业绩。” 进入【新浪财经股吧】讨论相关的主题文章: